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Abstract 
 In recent years, a series of regulatory actions have reformed the 
Italian pharmaceutical supply chain, particularly that of non-prescription 
drugs. The present study analyzes the distribution phase of non-prescription 
drugs. Specifically, it focuses on the retail market of pharmaceuticals in 
Italy, highlighting the different sales formats and the role played by those 
large-scale retailers that have been able to develop new pharmaceutical 
offerings in their point of sales through dynamic management of retailing 
mix levers in a competitive perspective. 
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Introduction 
 Large-scale retailing in the grocery sector is currently characterized 
by a limited number of companies operating on different market areas, which 
are continuously developing innovative market offerings. The high 
competition faced by large-scale retail companies while operating on these 
markets has forced them to implement different development/growth 
strategies aimed at maintaining or strengthening their competitive positions 
(Robinson and Clarke‐Hill, 1990; Basker et al., 2012; Riboldazzi, 2015a). In 
particular, common growth/development strategies implemented by large-
scale retail companies include the following: 
- strengthening and improving the productivity and efficiency of 
existing offering, with only small changes in assortments, keeping into 
account the retailer reference segment market; 
- upgrading the market offering, and sometimes the format, with 
reference to existing points of sale as well as to the opening of new points of 
sale in domestic or foreign markets; such upgrades can be achieved by 
developing and selling new goods or services related to the core offering, 
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able to meet segment market demand linked to the reference market of the 
retailer; 
- developing new product ranges unrelated to the core offering, with 
reference to existing points of sale as well as to the opening of new ones, to 
meet new domestic and foreign segment market demand. 
 Obviously, each development trajectory strictly depends on the 
specific innovation process being implemented by the company (Musso, 
2010). In particular, the choice to undertake a certain development trajectory 
rather than another one, along with the required innovation process, strictly 
relies on the retailer’s ability to swiftly identify and use to its advantage 
market opportunities deriving from changes in demand, offer, and 
environmental factors.  
 With regard to Italian market and other European markets, legislative 
reforms taking place in the last few years have allowed main large-scale 
retail companies to develop new market offerings in sectors far from their 
core business such as fuel, phone or finance services, and pharmaceuticals 
(Burt, 1991; Alexander and Pollard, 2000; Martinelli, 2012; Riboldazzi, 
2010, Risso, 2010).  
 Through analysis of secondary data, the present study specifically 
aims at describing the main features of the pharmaceutical supply chain in 
Italy as a result of the drug retail distribution reform, while focusing on the 
role of large-scale retail companies in such market. In particular, this study 
will address the main forms of non-prescription drug retailing, with a 
specific focus on the retailing mix and formats developed by large-scale 
grocery retail companies. 
 In our concluding remarks, we will take into consideration the 
relationship between innovation and development of the pharmaceutical 
offerings developed by large-scale retail companies. 
 
The distribution phase in the pharmaceutical supply chain in Europe 
 The pharmaceutical supply chain consists of a number of subjects, 
such as pharmaceutical industries, wholesalers, and retailers (e.g. retail 
pharmacies, drugstores, hospital pharmacies, etc.), which develop different 
business functions to meet drug demand.  
 The pharmaceutical industry is undoubtedly one of the most 
important industrial sector worldwide. Globally, only a few large companies 
play a relevant role in drug manufacturing (e.g. Novartis, Sanofi, Pfizer, 
Roche, and GlaxoSmithKline). Over the years, such companies have 
undergone many structural and operational changes such as mergers, 
acquisitions, horizontal, or vertical integrations, thereby achieving 
economies of scale. These companies are now characterized by global 
development, delocalization, diversification of activities, activation of 
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competitive and strategic alliances-—with competitors, biotechnological 
industries, hospitals, research institutes, and companies supplying specific 
devices and equipment—and high R&D investment to develop innovative 
pharmaceutical products.  
 Regarding production, companies involved in the global 
pharmaceutical industry (i.e. originator or branded companies), compete with 
other companies that manufacture generic drugs (e.g. Teva Pharmaceutical, 
Novartis, Actavis-Watson Pharmaceuticals, Mylan, and Sanofi), as well as 
with other minor companies in terms of product output and earnings, which 
include small/medium-sized enterprises specialized in the production of 
specific drugs, companies focused on specific indications or pharmaceutical 
formulations, and other companies specialized in innovation in well-defined 
and narrow sectors. 
 Among European countries, Switzerland, Germany, Italy, France, and 
the UK are the main manufacturers of pharmaceuticals (Efpia, 2016). With 
respect to the overall European pharmaceutical expenditure, the five most 
important markets are Germany, UK, France, Italy, and Spain. Notably, non-
prescription drug expenditure amounts to 15.8% of the entire European 
pharmaceutical market. In this scenario, the five most important markets for 
non-prescription drugs are Germany, France, UK, Italy and Poland (Centro 
Studi Assosalute, 2016). 
 Once drugs have gone through the various development phases, 
which vary according to product type (e.g. ethical drugs, OTC, generics, etc.) 
and geographical area where they are produced (Riboldazzi, 2015b), they 
enter the distribution phase of the pharmaceutical supply chain.  
 The first distribution phase concerns wholesale distribution, which 
specifically involves a limited number of companies purchasing 
pharmaceuticals in bulk from manufacturers and moving them along the 
supply chain, thus determining the final distribution phase. Wholesale 
distribution develops a large number of activities such as transfer, transport, 
storage, information, and financing. The importance of wholesaling in the 
pharmaceutical supply chain is further strengthened by the fact that small-
size orders and the high-frequency delivery often required by drug retailers 
can significantly hamper the efficiency of direct channel distribution (i.e. 
manufacturer-retailer). Specifically, a proximity service such as that 
provided by local pharmacies, characterized by assortment specialization and 
small/medium-sized points of sale, requires minimum storage provisions. 
This would not be possible without the help of wholesalers that reduce 
logistics and transaction costs, secure a rapid and continuous supply of 
medical products, and generate value along the pharmaceutical supply chain 
by providing additional services (e.g. information on new products on the 
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market or on drug prices, collection and disposal of expired drugs, credit on 
supplies, etc.) (Riboldazzi, 2012). 
 In the European market, wholesale distribution may include full-line 
or short-line wholesalers as well as other subjects like logistics operators, or 
groups and pharmacy cooperatives. Full-line wholesalers generally manage 
big stocks of drugs, which they own and operate at the regional, domestic 
and/or European level. Instead, short-line wholesalers operate outside the 
public service and deal with pharmaceutical and parapharmaceutical 
products of one or few manufacturers, with whom they stipulate exclusive 
fixed-term agreements—short-line wholesaling is not present in Italy. 
 Despite wholesale distribution across Europe being characterized by 
country-specific organizational models rather than regional ones, from a 
general standpoint, it can be argued that while in the countries of northern 
Europe there can be found an increasingly higher number of multinational 
distribution operators, in the countries of southern Europe there is a higher 
number of wholesalers, with pharmacy cooperatives playing a major role. 
 In a way similar to what seen for drug manufacturers, also companies 
involved in wholesaling have undergone profound structural and 
organizational changes through acquisitions, mergers, horizontal integrations 
among competitors, vertical integrations between pharmacies and pharmacy 
groups (i.e. downstream), or producers of generic or non-prescription drugs 
(upstream), also with regard to private label drug production. Thus, 
concentration and rationalization do characterize European wholesale 
distribution, where the three main operating groups are Celesio, Alliance 
Boots, and Phoenix—they account for 60% of the European wholesale 
market and own 35% of European pharmacy chains, besides controlling 
about one third of independent pharmacies grouped in cooperatives (Centro 
Studi Assosalute, 2016). 
 As far as the Italian market is concerned, wholesale distribution is 
characterized by the presence of two main subjects: depositaries and 
wholesalers. The latter ones, being owners of the goods they transfer, can 
work locally with a single warehouse, across regions with more than one 
warehouse, or be part of purchasing groups bringing together pharmacy 
cooperatives. In Italy, like in the rest of Europe, there have also been a 
number of wholesale companies undergoing mergers, acquisitions or 
integrations, even though with a lower frequency, with the first three groups 
currently accounting for about 50% of the market. In recent years, Alliance 
and Comifar, the two leading Italian wholesale companies, owned by 
Alliance Boots and Phoenix, respectively, have considerably increased their 
presence on the territory by purchasing domestic operators or public 
pharmacy shares, and joining parapharmacy chains to strengthen their 
competitive positions. About 33% of wholesalers’ turnover is generated by 
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distribution to retailers, especially pharmacies selling non-prescription drugs 
and parapharmaceuticals, with the remainder being constituted by ethical 
drugs. 
 Hence, through wholesaling—57.6% of non-prescription drugs are 
distributed through wholesale, while the rest is distributed directly (Centro 
Studi Assosalute, 2016)—, drugs can finally reach the retail distribution 
phase, which involves a large number of retailers (e.g. retail pharmacies, 
drugstores, hospital pharmacies, and dispensing doctors), which are widely 
spread throughout the territory, with pharmacies being the dominant channel. 
Table 1. Pharmaceutical wholesale and retail distribution in selected European countries. 
 
Distribution 
phase 
Italy France 
German
y 
Netherl
ands 
Spain 
United 
Kingdo
m 
Distributio
n system 
 
Multi-
channel 
Multi-
channel 
Multi-
channel 
Multi-
channel 
Multi-
channel 
Multi-
channel 
Distributio
n channel 
Wholesale 
Full-
line, 
direct 
sale 
Full-
line, 
short-
line, 
direct 
sale 
Full-
line, 
short-
line, 
direct 
sale 
Full-line, 
short-line, 
direct sale 
Full-line, 
short-line, 
direct sale 
Full-line, 
short-
line, 
direct 
sale 
Full-line 
wholesalers 
38 17 13 5 51 9 
of which 
- full-line  
domestic 
wholesalers 
 
2 3 5 3 3 3 
Non-
prescriptio
n 
drug sale in 
physical 
channels 
different 
from 
pharmacies  Retail 
Yes  No 
Yes – 
General 
Sale 
List 
Yes – 
General 
Sale List 
No 
Yes – 
General 
Sale List 
Online sale Yes Yes Yes Yes Yes Yes 
Territorial 
restrictions 
for the 
opening of 
pharmacies 
Yes Yes No No Yes No 
Source: Data analysis of the Author based on data from Centro Studi Assosalute 2016 and 
AESMD – Association of the European Self-Medication Industry. 
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 The latter is the only physical distribution channel for many 
European countries, such as France, Belgium, Austria, Finland, Spain, and 
Greece, even though in some of these countries there may be some 
exceptions. For instance, in Finland it is possible to buy outside pharmacies 
only pharmaceuticals based on nicotine provided that the seller has a sales 
tax permit. Moreover, pharmaceutical assistance programs can supply OTC.  
 In contrast, in many other countries, all or the majority of non-
prescription drugs can be sold through non-pharmacy channels. Finally, in 
almost all European countries it is allowed to sell drugs online. 
 
Drug retail distribution in Italy 
 Since 2005, the Italian drug retail distribution system has been 
radically reformed thanks to a series of regulatory actions, among which we 
can highlight the following (Federfarma, 2015): 
-  “Bersani” Law-2006. According to this law, non-prescription drugs 
(i.e. OTC and SOP) are allowed to be sold in non-pharmacy channels, 
provided that such stores guarantee the presence of a pharmacist and make 
available an area dedicated exclusively to the sale of drugs (i.e. corners in 
large-scale retail stores). Furthermore, it allows the opening of stores able to 
sell non-prescription drugs just by written communication to the Ministry of 
Health and the Region. The “Bersani” Law has also put an end the 20% 
discount limit applicable to drugs, enforced in 2005 by the “Storace” Decree. 
Moreover, it stipulates that pharmacists can own up to four pharmacies, 
eliminates any incompatibility between wholesale distribution and 
distribution to consumers of drugs, and finally reduces to two years the 
deadline given to the heirs of pharmacy owners to decide whether to take 
ownership or surrender the pharmacies (Leg. Decree No. 201/2011, turned 
into Law No. 214/2011).  
- Finance Act of 2007. It establishes that each point of sale can decide 
autonomously the selling price for non-prescription drugs, and eliminates 
any restrictions applied on pharmacy advertisement (Pharmacist Code of 
Conduct).  
- Leg. Decree No. 201/2011, turned into Law No. 214/2011. It allows 
discounts also on Group C prescription drugs. Furthermore, in 2011 there 
was an increase in the range of drugs to be sold in stores in the presence of a 
pharmacist, while delisting some drugs previously subject to prescription.  
- “Cresci Italia” Decree of 2012. It reduces the ratio between 
pharmacies and residents from 1/5,000 to 1/3,300—specifically from 1/4,000 
in places with more than 12,500 inhabitants and 1/5,000 in places with less 
than 12,500 inhabitants—allowing the opening of pharmacies, 
notwithstanding the quorum, in highly-frequented places such as shopping 
malls, railway stations, and so on. Moreover, the “Cresci Italia” Decree 
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liberalizes the opening hours and allows the discount for all drugs being 
purchased by Italian citizens. Furthermore, it reduces to 6 months, following 
submission of the Statement of Succession, the term given to heirs of 
pharmacy owners to take ownership or surrender the pharmacy. Finally, it 
legalizes sales of prescription veterinary drugs and galenic compounds in 
general stores. The Leg. Decree known as “Concorrenza” acknowledges the 
possibility for limited companies to own pharmacies and start-up pharmacy 
chains (Federfarma, 2015). 
- Leg. Decree of February 19th, 2014. It legalizes online sales of only 
non-prescription drugs, both self-medication/OTC and SOP, according to 
specific procedures, for all businesses holding a license for the sale of non-
prescription medicinal products (Centro Studi Assosalute, 2015). 
 The aforementioned norms have profoundly reformed the structure, 
competitiveness, and operations of Italian retailers, which in recent years 
have been trying to shape an increasingly effective and efficient business 
model by improving their services, implementing cutting-edge retailing mix 
policies through the diversification of their market offerings, and forming 
partnerships and strategic alliances between companies. 
 In particular, due to the above-mentioned structural changes, the 
retail system of non-prescription drug retail distribution is now characterized 
by the following aspects: 
- Multi-channel marketing. In the years prior to the drug retail 
distribution reform, the sale of drugs was only allowed in pharmacies, 
thereby making the pharmacy channel a true monopoly. The dominant 
position of pharmacies in the drug market was also due to the fact that 
medicinal products were regarded as atypical goods. Nonetheless, 
pharmacies could also sell other products related to health, which were not 
reserved exclusively for the pharmacy channel (e.g. homeopathic goods, 
nutritional supplements, herbal, dietetic and nursery products, as well as 
parapharmaceuticals and cosmetics). Following the reform, non-prescription 
drug retail distribution has shifted from mono-channel to multi-channel 
distribution, thereby allowing the purchase of drugs in more than one format, 
such as pharmacies, parapharmacies, large-scale retail stores, and online 
channels. 
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Figure 1. Changes in non-prescription drug sales volumes in the three physical sales 
channels. Sell out 2007-2015. 
 
Source: Centro Studi Assosalute, 2016.  
 
- Increase in the number of pharmacies, especially small-sized 
pharmacies, where it is possible to buy pharmaceuticals. Although the 
opening of new pharmacies still remains regulated by the Organization Chart 
(i.e. “Pianta Organica”), in compliance with the “Cresci Italia” Decree, there 
has been a consistent reduction in the number of residents required for the 
opening of new points of sale. The reform has also simplified procedures for 
the opening and assignment of pharmacies, as well as the management of 
inheritance, personnel hiring, shifts, opening hours and discounts. In the last 
decade, the amount of pharmacies which sell non-prescription drugs in the 
domestic territory has therefore increased considerably—from about 16,000 
to 18,609 stores—(Centro Studi Assosalute, 2005, 2016), especially the 
number of small-sized pharmacies (i.e. pharmacies with a revenues of less 
than 327,000.00 € per year) (Centro Studi Assosalute, 2016). Furthermore, 
pharmacies have been steadily refining their marketing policies and services. 
In particular, local pharmacies are now offering healthcare services to 
citizens such as booking of specialist outpatient services, collection of 
medical reports, and so on. 
- Increase in the number of parapharmacies and corners in large-scale 
retail stores. In the last decade, following liberalization, the total number of 
parapharmacies and corners in large-scale retail stores selling non-
prescription drugs has more than doubled. 
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Figure 2. Number of parapharmacies and corners in large-scale retail stores 2007-2015 
 
Source: Centro Studi Assosalute, 2016. 
 
 Although pharmacies still remain the main physical channel for 
medicinal product sale (e.g. ethical drugs, SOP, OTC), they are quickly 
losing market shares in favor of other channels, for which, however, drug 
sale is a small revenue source in comparison with that derived from the sale 
of other health-related products (e.g. parapharmaceutical, dietary, personal 
hygiene, beauty, hygiene, and notified products; herbal homeopathic 
remedies, nutritional supplements, and medical-surgical devices). For 
example, in corners of large-scale retail stores the share of non-prescription 
drugs and non-pharmaceutical products amount to 9.9 and 90.1% of total 
sale, respectively. 
 Pharmacies offer on average a wider assortment of SOP and OTC 
drugs compared to that offered by parapharmacies and corners of large-scale 
retail stores, whereas corners tend to mainly focus on high-turnover products. 
Moreover, with regard to the number of points of sale, corners in large-scale 
retail stores grow at a slower pace than parapharmacies, partially because 
such corners are usually opened in large format (e.g. superstores and 
hypermarkets). However, small-medium sized formats appear to be more 
successful in the Italian market (e.g. supermarkets). An example is 
represented by Coop, the first large-scale distribution company in Italy with 
a turnover of 12.42 billion euros, which operates on the domestic territory 
with 102 hypermarkets and 1,087 supermarkets. It entered the 
pharmaceutical market in 2006, and in July 2015 its corners amounted to a 
staggering total of 129, of which 101 were located in hypermarkets and 8 in 
supermarkets. Coop’s corners offer an assortment of about 2,900 items, of 
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which about 2,300 consists of parapharmaceuticals. Coop is also the only 
company to have developed and commercialized private label drugs (i.e. 
acetylsalicylic acid + ascorbic acid, paracetamol, calefred, carbocysteine 
syrup, acetylcysteine, and flurbiprofen mouthwash and spray) (Coop, 2014). 
 
Retailing mix in the pharmaceutical offering of large-scale retail 
companies vs. the pharmacy channel. 
 Following a market-driven approach (Brondoni, 2008; Brondoni, 
2009; Gnecchi, 2009; Brondoni and Musso, 2010; Brondoni et al., 2013), 
large-scale retail companies in the grocery sector have undergone a 
continuous process of development and growth highly influenced by market 
opportunities. One example is represented by the pharmaceutical market 
reform, which large-scale retailers, especially those with a high market share, 
have been able to promptly seize and exploit to their advantage. Indeed, 
towards the end of 2007, the year following the introduction of the “Bersani” 
Law, about 160 pharmaceutical corners were operating on the Italian market. 
Since then, their number has increased. This success is likely due to a much 
more efficient service offered by this sale channel compared to that offered 
by parapharmacies or pharmacies. This improved efficiency and efficacy can 
be probably ascribed to the expertise, abilities, relationships, technologies, 
and managerial skills that such enterprises have accrued over time. 
Moreover, supply organization, choices on assortment, decisions on private 
labels, pricing, and communication policies as well as merchandising 
activities are all heavily centralized, thus providing an advantage typical of 
economies of scale.   
 A thorough evaluation of the retailing mix levers (i.e. assortment, 
private label, merchandising, communication, and pricing) clearly points to 
the peculiarity of large-scale retail corners with respect to pharmacies, the 
main format of drug sale. 
 Generally, the assortment consists of the whole range of products 
made available to consumers at a certain place, time, and price. Assortment 
policy levers include breath, depth, and variety that can be assessed either at 
the distribution or category level. If the analysis is carried out at the 
distribution/point of sale level, the extent of assortment breadth is defined by 
the number of product categories offered by the store. A measure of variety, 
on the other hand, is given by the number of consumption segments offered 
for each category. Finally, the extent of depth is directly proportional to the 
number of brands offered for each consumption segment. 
 With regard to breadth and depth, it is possible to define four kinds of 
assortment based on their specialization degree (Baccarani, 2001). An all-
encompassing assortment is characterized by high levels of breadth and 
depth (i.e. stores make available a large number of varieties and sizable 
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quantities of products able to meet different customer needs). The opposite 
situation, which takes place when both breadth and depth are considerably 
downsized, gives rise to the emergency assortment, which is developed to 
meet sudden customer needs. When we register low levels of depth and high 
levels of breadth, we can define the assortment as despecialized. Conversely, 
a specialized assortment is characterized by high depth and low breadth 
levels. 
 When we consider single pharmacies, we can observe that all these 
formats have developed a specialized assortment—all market offerings are 
aimed at treating and/or preventing diseases and developing wellness. In 
contrast, large-scale retailers can sell pharmaceutical products in either 
specialized stores outside large-scale groceries—in this case, they develop a 
specialized assortment format—or inside despecialized stores (e.g. 
superstores, hypermarkets, etc.). In this regard, despecialization is achieved 
by modifying both core and peripheral offerings: the core offering is 
enriched by the addition of new product categories (e.g. drugs and health 
products), whereas the peripheral offering is improved by the introduction of 
ancillary services related to the sale of drugs (i.e. pre-sale, sale, and post-
sale). Thus, in recent years, large-scale retailers have become increasingly 
despecialized due to the inclusion in their traditional offerings (e.g. food, 
household and pet products) of several new product categories such as drugs 
and health products. 
 With regard to assortment composition, it is important to point out 
that pharmacy assortments are generally made up of pharmaceutical 
specialties, extra-pharmaceuticals, or non-pharmaceuticals. Pharmaceutical 
specialties include special medicines (i.e. ethical drugs, SOP and OTC) or 
generics (i.e. semi branded, branded and unbranded). Ethical drugs can only 
be purchased with a prescription, while SOP and OTC do not require any 
prescription. Generics contain active ingredients equivalent to those of other 
drugs whose patent has already expired, and can be classified into 
prescription or non-prescription drugs. Extra-pharmaceuticals are a 
significant source of profit for pharmacies, because they include different 
product lines such as non-notified OTC, in vitro diagnostic chemical devices, 
medical devices (e.g. syringes, needles etc.), complementary medicine (e.g. 
herbal and homeopathic drugs), nutrition and hygiene baby care products, 
nutritional supplements for celiac disease or diabetes patients, cosmetics, 
hygiene products for the body and oral cavity, perfumery products, 
parapharmaceuticals (e.g. dressing or orthopedic products), and veterinary 
goods (Cuomo et al., 2010). 
 Large-scale retail corners, unlike pharmacies, cannot sell drugs that 
need medical prescription; their assortment is therefore mainly based on non-
prescription drugs, extra-pharmaceuticals, and non-pharmaceuticals. 
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 Specifically, non-prescription drugs include the following: 
- OTC; i.e. drugs that can be promoted to the public and are easily 
accessible in the point of sale (i.e. self-service); 
- SOP; i.e. drugs that cannot be promoted to the public and are not 
easily accessible in the point of sale. 
 Non-pharmaceutical products can be generally classified into notified 
products (e.g. nutritional or dietary supplements, medical devices, herbal 
preparations, homeopathic drugs, and medical-surgical equipment), 
nutritional products, parapharmaceuticals (e.g. medical-surgical or diagnostic 
instruments, wound care products, eye care products, and products for 
children and the elderly) as well as unregistered hygiene and beauty products 
(Centro Studi Assosalute, 2015). Notably, notified products have a 
considerably lower importance here than in other channels. As a result, a 
major part of the assortment and sales is constituted by nutritional, hygiene, 
and beauty products, which represent about 43% of total sales of non-
pharmaceutical products (Centro Studi Assosalute, 2016). 
 Corners can also sell non-prescription galenic compounds as well as 
veterinary drugs with prescription. In addition, all stores licensed to sell non-
prescription drugs, including large-scale retail corners, can sell their products 
online in compliance with Italian regulations. Finally, although private label 
products can be part of the assortment, in the Italian market, only the leading 
brand Coop Italia has been able to develop several private label products, 
generating savings of up to 50% on average (Coop, 2014; Coop 2015). 
 Merchandising policies coincide with assortment strategies, which 
mainly relate to store and merchandise layout and display space allocation. 
Such strategies are not only aimed at improving overall profit, but also at 
respecting competitive market relations, especially those among suppliers, 
notwithstanding the need to create added value for customers and increase 
profitability. 
 With regard to store layout, two joint models are usually chosen by 
large-scale retail corners: the grid model and the free flow/boutique model. 
While the former increases the display surface compared to the total 
available surface of a store, thus generating higher revenues, the latter 
simplifies the consumer purchase process, thereby meeting increasingly 
higher information needs.  
 Regarding merchandise layout, many retailers tend to group together 
similar categories of products and place side by side categories having 
similar use (e.g. products for cardiovascular disease), same customers (e.g. 
pregnant women), or same period of sale (e.g. suntan lotions). 
 As for space allocation given to product lines in large-scale retail 
stores, we can often notice dispersion in the case of goods with an high 
frequency of purchase, and, conversely, a more effective placement of those 
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products with a greater unitary margin (i.e. margin placement). Since the 
choice of this space allocation might create confusion in the customer, many 
large scale retailers tend to develop their assortments according to visual 
merchandising principles based on “exhibit clarity”. We can thus distinguish 
three main types of placements: 1) segment vertical display and brand 
horizontal display for product family; 2) segment vertical display and brand 
vertical display for product family; 3) brand vertical display and segment 
horizontal display for product family; 4) brand vertical display and segment 
vertical display for product family.  
 As far as merchandising is concerned, large-scale retail corners 
appear to give greater importance to merchandising (e.g. store and 
merchandise layout and display space allocation) with respect to pharmacies, 
especially small or medium-sized stores, where the display of products is 
frequently organized in a different way than what described above. Indeed, 
large-scale retail distributors apply the same management principles for drug 
display as those adopted for other products, according to corporate store 
brand policies, with the final goal of improving store sales performance 
through optimization of intra- and inter-product display opportunities across 
the entire point of sale. Pharmaceutical display therefore depends on general 
merchandising policies implemented by the point of sale aimed at the 
following goals: 1) increasing sales volume of highly marginal products; 2) 
“leveling” demand spikes; 3) optimizing profits of family, line, or single 
products; 4) building and strengthening the store brand image; 5) minimizing 
surplus and inventories; 6) maximizing product display opportunities 
(Riboldazzi, 2007). 
 Finally, in both pharmacies and large-scale retail corners there can be 
often found a customer care/waiting area placed between a self-service area 
and the behind-the-counter area, which is intended for the exclusive use of 
the pharmacist, and where all drugs that cannot be directly purchased by 
customers are stored. In corners, behind-the-counter drugs are for the major 
part non-prescription SOPs, whereas in pharmacies these drugs include non-
prescription SOPs together with ethical drugs and generics requiring medical 
prescription. 
 Focusing on communication policies, it can be argued that 
pharmaceutical retailers often combine marketing communication with 
institutional and organizational communication. In this context, 
communication mainly pertains to products, brands, and companies. 
Common types of marketing communication include in-store communication 
(e.g. in-store signage), promotions (e.g. discounts, vouchers, etc.), direct 
marketing (e.g. loyalty cards and sms) and media advertising (i.e. 
advertisement published on journals or specialized magazines). In particular, 
with regard to drug assortment communication, companies are supposed to 
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comply with Italian Law regulations, such as Leg. Decree No. 219/2016, 
which establishes that only OTC can be subject to marketing 
communication. The decree and its subsequent amendments also determines 
both minimum and banned content, which, before being disseminated, must 
be in any case approved by a regulatory body appointed by the Ministry of 
Health—the authorization has a two-year expiration date. Regarding health 
products, such as nutritional supplements or herbal drugs, except for medical 
devices, no prior authorization is required. These products are therefore less 
subject to strict legislative restrictions compared to other drugs, even though 
non-pharmaceutical product advertisement should not refer by any means to 
the possibility of preventing, treating, and healing any forms of human 
disease.  
 In addition, on February 17th, 2010 the Ministry of Health provided a 
series of guidelines for regulating online advertising, toll-free numbers, SMS 
and MMS (Centro Studi Assosalute, 2016). Contrary to pharmacies, large-
scale retail corners can also benefit from all combined communication 
policies developed by the point of sale and the distribution chain. 
Furthermore, pharmaceutical offerings often mirror the overall mission of the 
large-scale retailer.  
 About communication tools, many corners often resort to traditional 
in-store communication or communication through new technologies (e.g. 
general, departmental or linear signage, in-store leaflets, in-store radio, self-
scanning, e-labels, in-store videos, etc.). Moreover, large-scale retailers often 
use promotions and cross promotions such as discount vouchers for future 
purchases of drug after a minimum amount purchase. 
 Finally, considering the price lever, we can notice that the pricing 
system of non-prescription drugs has been liberalized; hence prices can be 
fixed by each single point of sale, provided that the highest ex-factory price 
and any upward changes are promptly communicated to AIFA. Moreover, it 
is no longer mandatory to display the drug price on a label (Centro Studi 
Assosalute, 2015).  
 Overall, drug pricing appears to be influenced by a number of 
internal variables (e.g. expenditures for store, warehouse, and management) 
and external variables (e.g.  environment and competition) as well as factors 
linked to business goals (e.g. market shares, competitive positioning, etc.). 
 Following the drug retail distribution reform, price competition for 
OTC, SOP, parapharmaceuticals and extra-pharmaceuticals has dramatically 
increased and therefore price variations have become more and more 
frequent. In corners, such price variations take place at a much faster pace 
than other formats probably because large-scale retailers need to quickly 
react to changes in competitors’ pricing strategies while keeping into account 
the short-term goals of the product category, brand promotional policies, 
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relationships with suppliers and, lastly, the added value provided to the 
customer with respect to such competitors. 
 
Conclusion 
 In the last few years, the Italian large-scale drug retail system has 
undergone a series of regulatory actions that have modified its structure, 
competitiveness, and operations. In particular, 1) the sale of non-prescription 
drugs has been legalized not only in pharmacies, but in other stores as well, 
such as parapharmacies and points of sale managed by large-scale retailers; 
2) the quantity of pharmacies has dramatically increased; 3) the role of 
parapharmacies and above all large-scale retailers in the sale of non-
prescription drugs and extra-pharmaceutical products has become prominent.  
 The reason large-scale retailer have been so successful in drug sales 
can be traced to the skills, expertise, state-of-the art technologies, networks, 
and economies of scale that such retailers have been able to develop over 
time, while striving to achieve efficient and profitable services. Indeed, in 
large-scale retail corners, pharmaceutical retailing mix levers are managed 
dynamically and in a competitive perspective. Hence, large-scale retailers, 
thanks to dynamic product assortment aggregation, visual merchandising 
optimization, competitive pricing, and efficient communication management 
have been able to quickly develop and launch on the market value-added 
pharmaceutical offerings and, consequently, achieve drug category 
objectives according to overall store brand orientations. 
 Moreover, the choice of large-scale retail distributors to sell drugs 
has spread innovation, thereby improving customer loyalty. When drugs are 
sold in dedicated stores, innovation refers to point of sale portfolio (e.g. 
superstores, hypermarkets, supermarkets, etc.), which thus gains a new 
specialized format, the pharmacy. When drugs are sold in already existing 
formats (e.g. areas inside supermarkets), innovation comes from the 
commercial offering itself, which increases its breadth through the addition 
of pharmaceuticals and ancillary services to its assortment. 
 Specifically, the pharmaceutical offering by large-scale retailers 
generates innovation in: 
 1) business functions developed by such retailers, which now 
includes other complementary functions (e.g. supply, transport, storage, etc) 
aimed at supporting the management of new pharmaceutical product 
categories; 
 2) market offering meant as the combination of those different 
attributes (e.g. pre-selection, service speed, comfort and pre-sale, sale and 
post-sale services) that form the entire format. The core offering is improved 
thanks to the introduction of new pharmaceutical product categories, whereas 
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the peripheral offering is enhanced by the development of pre-sale, sale and 
post-sale services related to the sale of such categories. 
 3) retailing mix, especially with regard to assortment policy 
management, private labels, pricing, communication, and visual 
merchandising, which all vary because of the management of the 
pharmaceutical product category, which ultimately relies on the team effort 
among the categories offered in the store.  
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